We are live on ! Find out more
ALPN

Alpine Immune Sciences Inc
ALPN

Delisted

ALPN was delisted on the 17th of May, 2024.

Back to rankings

48 hedge funds and large institutions have $145M invested in Alpine Immune Sciences Inc in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

50% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 10

9% more funds holding

Funds holding: 44 → 48 (+4)

10% less capital invested

Capital invested by funds: $160M → $145M (-$15.4M)

Holders
48
Holders Change
+4
Holders Change %
+9.09%
% of All Funds
0.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
15
Reduced
10
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$3.74M
2
SCM
Soleus Capital Management
Connecticut
+$3.39M
3
APM
Avidity Partners Management
Texas
+$3.28M
4
Deutsche Bank
Deutsche Bank
Germany
+$3.05M
5
OM
Opaleye Management
Massachusetts
+$1.95M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$4.64M
2
FCM
Farallon Capital Management
California
-$2.52M
3
CCM
CAAS Capital Management
New York
-$1.87M
4
EI
EAM Investors
California
-$797K
5
Renaissance Technologies
Renaissance Technologies
New York
-$772K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$32.6M – – –
FM
2
Frazier Management
Washington
$27.3M – – –
APM
3
Avidity Partners Management
Texas
$16M +$3.28M +263,000 +21%
OFM
4
Omega Fund Management
Massachusetts
$13.6M – – –
EC
5
EcoR1 Capital
California
$7.86M – – –
AG
6
Artal Group
Luxembourg
$6.29M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$6.1M +$345K +27,700 +5%
SB
8
Samsara BioCapital
California
$4.23M – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$4.21M -$772K -61,900 -13%
SCM
10
Soleus Capital Management
Connecticut
$3.32M +$3.39M +272,000 +662%
IC
11
Ikarian Capital
Texas
$3.23M +$3.74M +300,000 +6,330%
Deutsche Bank
12
Deutsche Bank
Germany
$2.59M +$3.05M +244,332 New
SFM
13
Sphera Funds Management
Israel
$2.1M – – –
OM
14
Opaleye Management
Massachusetts
$1.66M +$1.95M +156,500 New
TM
15
Tiger Management
New York
$1.46M – – –
PVI
16
Pura Vida Investments
New York
$1.4M -$63.9K -5,127 -4%
Two Sigma Advisers
17
Two Sigma Advisers
New York
$1.33M +$289K +23,200 +23%
DCM
18
DAFNA Capital Management
California
$1.2M +$1.25K +100 +0.1%
Two Sigma Investments
19
Two Sigma Investments
New York
$1.14M -$512K -41,062 -28%
Millennium Management
20
Millennium Management
New York
$1.02M +$626K +50,246 +110%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$976K +$186K +14,915 +19%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$633K +$745K +59,728 New
Ensign Peak Advisors
23
Ensign Peak Advisors
Utah
$579K +$231K +18,505 +51%
Acadian Asset Management
24
Acadian Asset Management
Massachusetts
$515K +$572K +45,898 +1,737%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$480K -$35.6K -2,854 -6%
1
2 3

ALPN Hedge Fund Activity: Q1 2021 in Review

48 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q1 2021, worth a combined $145M — down 9.6% from $160M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ALPN positions and 7 closed out — a net gain of 4 holders — while 15 added to existing stakes and 10 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $3.74M. The largest seller was Morgan Stanley, cutting an estimated $4.64M.

  • 48 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q1 2021, up from 44 in Q4 2020.
  • Funds reported $145M of Alpine Immune Sciences Inc stock for Q1 2021, down 9.6% quarter-over-quarter.
  • 11 funds opened new Alpine Immune Sciences Inc positions in Q1 2021 and 7 closed out, a net change of +4 holders.
  • The largest Alpine Immune Sciences Inc buyer in Q1 2021 was Ikarian Capital, an estimated $3.74M added.
  • The largest Alpine Immune Sciences Inc seller in Q1 2021 was Morgan Stanley, an estimated $4.64M sold.

Based on aggregated 13F filings for Q1 2021.